ResMed Non-GAAP EPS of $2.55 beats by $0.05, revenue of $1.3B misses by $30M

* ResMed press release [https://seekingalpha.com/pr/20287382-resmed-inc-announces-results-for-the-first-quarter-of-fiscal-year-2026] (RMD [https://seekingalpha.com/symbol/RMD]): Q1 Non-GAAP EPS of $2.55 beats by $0.05.
* Revenue of $1.3B (+6.6% Y/Y) misses by $30M.
*

Q2 Revenue consensus of $  
1.40B

Q2 EPS consensus of $  
2.69

FY Revenue consensus of $  
5.60B

FY EPS consensus of $  
10.79

Click to enlarge

MORE ON RESMED

* ResMed Inc. (RMD) Presents at Bank of America Global Healthcare Conference 2025 Transcript [https://seekingalpha.com/article/4825139-resmed-inc-rmd-presents-at-bank-of-america-global-healthcare-conference-2025-transcript]
* ResMed: A Dividend Opportunity In The MedTech Space As The Company Grows [https://seekingalpha.com/article/4817070-resmed-a-dividend-opportunity-in-the-medtech-space-as-the-company-grows]
* ResMed Q1 2026 Earnings Preview [https://seekingalpha.com/news/4510363-resmed-q1-2026-earnings-preview]
* Short bets on S&P 500 Healthcare sector eases in August; MRNA stays most shorted stock [https://seekingalpha.com/news/4494706-short-bets-on-sp-500-healthcare-sector-eases-in-august-mrna-stays-most-shorted-stock]
* Seeking Alpha’s Quant Rating on ResMed [https://seekingalpha.com/symbol/RMD/ratings/quant-ratings]